메뉴 건너뛰기




Volumn 9, Issue 1, 2017, Pages 5-11

Rethinking the INN system for therapeutic antibodies

Author keywords

Allotypes; bispecific; Fc portion; IgG; INN; International Nonproprietary Name; monoclonal antibody; pharmacokinetics; recombinant; variants

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; RECOMBINANT ANTIBODY;

EID: 85001968823     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2016.1255520     Document Type: Note
Times cited : (11)

References (33)
  • 2
    • 84871612935 scopus 로고    scopus 로고
    • World Health Organization. General policies for monoclonal antibodies. 2009; http://www.who.int/medicines/services/inn/Generalpoliciesformonoclonalantibodies2009.pdf
    • (2009) General policies for monoclonal antibodies
  • 3
    • 85008882142 scopus 로고    scopus 로고
    • Jallal B., Vaughan T., Osbur J., (eds), Wiley
    • Watier H, Reichert J. Evolution of antibody therapeutics (Chapter 2). In:Jallal B, Vaughan T, Osbur J, eds Protein Therapeutics. Wiley, 2016 in press
    • (2016) Protein Therapeutics
    • Watier, H.1    Reichert, J.2
  • 5
    • 0033866627 scopus 로고    scopus 로고
    • Antibody humanization: a case of the “Emperor”s new clothes’?
    • Clark M. Antibody humanization:a case of the “Emperor”s new clothes’? Immunol Today 2000; 21:397–402; PMID:10916143; http://dx.doi.org/10.1016/S0167-5699(00)01680-7
    • (2000) Immunol Today , vol.21 , pp. 397-402
    • Clark, M.1
  • 6
    • 84918578141 scopus 로고    scopus 로고
    • The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region
    • PMID:25342759; annrheumdis-2014-206237
    • Van Schie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GJ, Rispens T. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis 2015; 74:311–4; PMID:25342759; http://dx.doi.org/10.1136/ annrheumdis-2014-206237
    • (2015) Ann Rheum Dis , vol.74 , pp. 311-314
    • Schie, K.A.1    Hart, M.H.2    de Groot, E.R.3    Kruithof, S.4    Aarden, L.A.5    Wolbink, G.J.6    Rispens, T.7
  • 7
    • 84897869100 scopus 로고    scopus 로고
    • Immunogenicity of therapeutic proteins: influence of aggregation
    • 23919460
    • Ratanji KD, Derrick JP, Dearman RJ, Kimber I. Immunogenicity of therapeutic proteins:influence of aggregation. J Immunotoxicol 2013; 11:99-109; PMID:23919460; http://dx.doi.org/10.3109/1547691X.2013.821564
    • (2013) J Immunotoxicol , vol.11 , pp. 99-109
    • Ratanji, K.D.1    Derrick, J.P.2    Dearman, R.J.3    Kimber, I.4
  • 8
    • 84962582891 scopus 로고    scopus 로고
    • Immunogenicity to Biotherapeutics - The role of anti-drug immune complexes
    • 26870037
    • Krishna M, Nadler SG. Immunogenicity to Biotherapeutics - The role of anti-drug immune complexes. Front Immunol 2016; 7:21; PMID:26870037; http://dx.doi.org/10.3389/fimmu.2016.00021
    • (2016) Front Immunol , vol.7 , pp. 21
    • Krishna, M.1    Nadler, S.G.2
  • 9
    • 84941183781 scopus 로고    scopus 로고
    • Monoclonal antibodies in excess: A simple way to avoid immunogenicity in patients?
    • 25930194
    • Chaigne B, Watier H. Monoclonal antibodies in excess:A simple way to avoid immunogenicity in patients? J Allergy Clin Immunol 2015; 136:814-6; PMID:25930194; http://dx.doi.org/10.1016/j.jaci.2015.03.013
    • (2015) J Allergy Clin Immunol , vol.136 , pp. 814-816
    • Chaigne, B.1    Watier, H.2
  • 10
    • 0035210960 scopus 로고    scopus 로고
    • Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies
    • 11717196
    • Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species:implications for therapeutic antibodies. Int Immunol 2001; 13:1551-9; PMID:11717196; http://dx.doi.org/10.1093/intimm/13.12.1551
    • (2001) Int Immunol , vol.13 , pp. 1551-1559
    • Ober, R.J.1    Radu, C.G.2    Ghetie, V.3    Ward, E.S.4
  • 11
    • 35648978158 scopus 로고    scopus 로고
    • Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment
    • 17624800
    • Magdelaine-Beuzelin C, Kaas Q, Wehbi V, Ohresser M, Jefferis R, Lefranc M-P, Watier H. Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment. Crit Rev Oncol Hematol 2007; 64:210-25; PMID:17624800; http://dx.doi.org/10.1016/j.critrevonc.2007.04.011
    • (2007) Crit Rev Oncol Hematol , vol.64 , pp. 210-225
    • Magdelaine-Beuzelin, C.1    Kaas, Q.2    Wehbi, V.3    Ohresser, M.4    Jefferis, R.5    Lefranc, M.-P.6    Watier, H.7
  • 12
    • 73449109876 scopus 로고    scopus 로고
    • World Health Organization. WHO Drug Information 2009; 23:195-9. http://www.who.int/medicines/publications/druginformation/issues/DrugInfo09vol23-2.pdf
    • (2009) WHO Drug Information , vol.23 , pp. 195-199
  • 17
    • 84910053743 scopus 로고    scopus 로고
    • Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis
    • 25058694
    • Thulliez M, Angoulvant D, Le Lez ML, Jonville-Bera A-P, Pisella P-J, Gueyffier F, Bejan-Angoulvant T. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies:systematic review and meta-analysis. JAMA Ophthalmol 2014; 132:1317-26; PMID:25058694; http://dx.doi.org/10.1001/jamaophthalmol.2014.2333
    • (2014) JAMA Ophthalmol , vol.132 , pp. 1317-1326
    • Thulliez, M.1    Angoulvant, D.2    Le Lez, M.L.3    Jonville-Bera, A.-P.4    Pisella, P.-J.5    Gueyffier, F.6    Bejan-Angoulvant, T.7
  • 18
    • 84903644131 scopus 로고    scopus 로고
    • MAbImprove: a French “Laboratoire d'excellence” (LabEx) dedicated to therapeutic antibodies
    • Pèlegrin A, Daguet A, Watier H. MAbImprove:a French “Laboratoire d'excellence” (LabEx) dedicated to therapeutic antibodies. MAbs 2014; 6:803-4; http://dx.doi.org/10.4161/mabs.29262
    • (2014) MAbs , vol.6 , pp. 803-804
    • Pèlegrin, A.1    Daguet, A.2    Watier, H.3
  • 19
    • 84899083197 scopus 로고    scopus 로고
    • Genetic variants of IgG1 antibodies and FcγRIIIa receptors influence the magnitude of antibody-dependent cell-mediated cytotoxicity against prostate cancer cells
    • 24701371
    • Pandey JP, Namboodiri AM. Genetic variants of IgG1 antibodies and FcγRIIIa receptors influence the magnitude of antibody-dependent cell-mediated cytotoxicity against prostate cancer cells. Oncoimmunology 2014; 3:e27317; PMID:24701371; http://dx.doi.org/10.4161/onci.27317
    • (2014) Oncoimmunology , vol.3 , pp. e27317
    • Pandey, J.P.1    Namboodiri, A.M.2
  • 20
    • 84918825382 scopus 로고    scopus 로고
    • IgG Subclasses and Allotypes: From structure to effector functions
    • Vidarsson G, Dekkers G, Rispens T. IgG Subclasses and Allotypes:From structure to effector functions. Front Immunol 2014; 5:1-17; http://dx.doi.org/10.3389/fimmu.2014.00520
    • (2014) Front Immunol , vol.5 , pp. 1-17
    • Vidarsson, G.1    Dekkers, G.2    Rispens, T.3
  • 23
    • 70349769842 scopus 로고    scopus 로고
    • Human immunoglobulin allotypes: possible implications for immunogenicity
    • 20073133
    • Jefferis R, Lefranc M. Human immunoglobulin allotypes:possible implications for immunogenicity. MAbs 2009; 1:332-8; PMID:20073133; http://dx.doi.org/10.4161/mabs.1.4.9122
    • (2009) MAbs , vol.1 , pp. 332-338
    • Jefferis, R.1    Lefranc, M.2
  • 25
    • 85008898085 scopus 로고    scopus 로고
    • Modifications in the IgG4 Fc portion of therapeutics in patents: opportunities for a twisting IgG subclass
    • Pottier J, Watier H, Gouilleux-Gruart V. Modifications in the IgG4 Fc portion of therapeutics in patents:opportunities for a twisting IgG subclass. Submitted 2016
    • (2016) Submitted
    • Pottier, J.1    Watier, H.2    Gouilleux-Gruart, V.3
  • 26
  • 28
    • 84926659212 scopus 로고    scopus 로고
    • Selection of IgG variants with increased FcRn binding using random and directed mutagenesis: impact on effector functions
    • 25657648
    • Monnet C, Jorieux S, Urbain R, Fournier N, Bouayadi K, De Romeuf C, Behrens CK, Fontayne A, Mondon P. Selection of IgG variants with increased FcRn binding using random and directed mutagenesis:impact on effector functions. Front Immunol 2015; 6:1-14; PMID:25657648; http://dx.doi.org/10.3389/fimmu.2015.00039
    • (2015) Front Immunol , vol.6 , pp. 1-14
    • Monnet, C.1    Jorieux, S.2    Urbain, R.3    Fournier, N.4    Bouayadi, K.5    De Romeuf, C.6    Behrens, C.K.7    Fontayne, A.8    Mondon, P.9
  • 29
    • 84950124556 scopus 로고    scopus 로고
    • Prevention and management of obinutuzumab-associated toxicities: Australian experience
    • 26681665
    • Snowden A, Hayden I, Dixon J, Gregory G. Prevention and management of obinutuzumab-associated toxicities:Australian experience. Int J Nurs Pract 2015; 21 Suppl 3:15-27; PMID:26681665; http://dx.doi.org/10.1111/ijn.12412
    • (2015) Int J Nurs Pract , vol.21 , pp. 15-27
    • Snowden, A.1    Hayden, I.2    Dixon, J.3    Gregory, G.4
  • 30
    • 84928210441 scopus 로고    scopus 로고
    • Ocular abnormalities in patients treated with a novel anti-GD2 monoclonal antibody, hu14.18K322A
    • 25818285
    • Tse BC, Navid F, Billups CA, O'Donnell T, Hoehn ME. Ocular abnormalities in patients treated with a novel anti-GD2 monoclonal antibody, hu14.18K322A. J AAPOS 2015; 19:112-5; PMID:25818285; http://dx.doi.org/10.1016/j.jaapos.2014.11.005
    • (2015) J AAPOS , vol.19 , pp. 112-115
    • Tse, B.C.1    Navid, F.2    Billups, C.A.3    O'Donnell, T.4    Hoehn, M.E.5
  • 32
    • 85008885540 scopus 로고    scopus 로고
    • International Nonproprietary Names for Pharmaceutical Substances (INN): Recommended International Nonproprietary Names List 75
    • World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN):Recommended International Nonproprietary Names List 75. WHO Drug Inf 2016; 75:19; http://www.who.int/medicines/publications/druginformation/innlists/RL75.pdf?ua=1
    • (2016) WHO Drug Inf , vol.75 , pp. 19
  • 33
    • 0015402447 scopus 로고
    • Localization of antibody-combining sites within the variable portions of heavy and light chains
    • 4560694
    • Inbar D, Hochman J, Givol D. Localization of antibody-combining sites within the variable portions of heavy and light chains. Proc Natl Acad Sci U S A 1972; 69:2659-62; PMID:4560694; http://dx.doi.org/10.1073/pnas.69.9.2659
    • (1972) Proc Natl Acad Sci U S A , vol.69 , pp. 2659-2662
    • Inbar, D.1    Hochman, J.2    Givol, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.